Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 12:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 3,411 matching trials from the live ClinicalTrials.gov search.
Conditions
Hematologic Neoplasm, HIV Infection
Interventions
GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Juvenile Myelomonocytic Leukemia, Neurofibromatosis Type 1
Interventions
Bone Marrow Aspiration and Biopsy, Trametinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more
Conditions
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Interventions
Dasatinib, Laboratory Biomarker Analysis, Venetoclax
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2040
U.S. locations
1
States / cities
Houston, Texas
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Study of Outcome After Therapy for Acromegaly

NCT01809808
Conditions
Acromegaly
Interventions
Surgery for acromegaly, Medications for acromegaly, Total body magnetic resonance imaging, Adipose Tissue Biopsy
Procedure · Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
rituximab, busulfan, carmustine, cyclophosphamide, cytarabine, etoposide, fludarabine phosphate, melphalan, total body irradiation (TBI), anti-thymocyte globulin IV
Biological · Drug · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Basal Cell Carcinoma, Basal Cell Nevus Syndrome
Interventions
Dietary Vitamin D3 pre-treatment, Photodynamic therapy, Serum Maintenance Vitamin D3
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Cleveland, Ohio
Conditions
Anxiety, Depression
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Leukemia
Interventions
daunorubicin hydrochloride, imatinib mesylate, prednisone, vincristine sulfate
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
5
States / cities
Duarte, California • Los Angeles, California • Stanford, California + 2 more
Conditions
Multiple Myeloma
Interventions
Zoledronic acid
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory
Interventions
REM-422
Drug
Lead sponsor
Remix Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Duarte, California • Tampa, Florida • Boston, Massachusetts + 2 more
Conditions
Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Interventions
parsaclisib, ruxolitinib, placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
36
States / cities
Anchorage, Alaska • Phoenix, Arizona • Berkeley, California + 29 more
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
CC-95251, Azacitidine, Venetoclax
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Palo Alto, California • Miami, Florida + 1 more
Conditions
Invasive Fungal Infections, Hematologic Malignancies
Interventions
Posaconazole, ABLC
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Germ Cell Neoplasms, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Immunodeficiency Diseases
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Symptomatic Osseous Bone Lesions From Any Malignancy
Interventions
Radiation Therapy, Quality-of-Life Assessment, Survey Administration
Radiation · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Neurofibromatosis Type 1
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
6 Years to 9 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia, Cytopenia
Interventions
rigosertib sodium
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
14
States / cities
Stanford, California • Chicago, Illinois • Westwood, Kansas + 7 more
Conditions
Myelodysplastic Syndromes
Interventions
Sertraline, Bone Marrow Aspirate/Biopsy
Drug · Procedure
Lead sponsor
Gustavo Rivero
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Houston, Texas
Conditions
Myelodysplastic Syndromes
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2052
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Bone Pain, Metastatic Malignant Neoplasm in the Bone, Plasma Cell Myeloma
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Other · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • Atlanta, Georgia + 4 more
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
busulfan, cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
16 Years to 55 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
65
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more
Conditions
Leukemia
Interventions
Ponatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Osteosarcoma, Malignant Fibrous Histiocytoma (MFH) of Bone
Interventions
Bevacizumab, Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, etoposide, Surgery, Radiotherapy
Biological · Drug · Procedure + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
5
States / cities
San Diego, California • Baltimore, Maryland • Bethesda, Maryland + 2 more
Completed Phase 2 Interventional Results available

The Effect of Etelcalcetide on CKD-MBD

NCT03960437
Conditions
Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Vascular Calcification, Hyperparathyroidism; Secondary, Renal
Interventions
Etelcalcetide
Drug
Lead sponsor
Thomas Nickolas, MD MS
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York